of HBeAg quantity at week 24 in predicting the efficacy of Peg-IFN-α 2a in HBeAg-positive CHB patients at week 48 and to find a useful predictor for treatment efficacy and investigate individualized plan of antiviral therapy.
PATIENTS AND METHODS

Patients
Ninety-six HBeAg positive CHB patients who have accepted antiviral therapy from September 2010 to October 2011 in Liver Diseases Department of Provincial Hospital affiliated to Shandong University were enrolled in this study. Eighty-six cases were male and 10 cases were female, aged from 20 to 35 years, mean age 27.2±3.2 years. The baseline of ALT was (196±73.6) U/L, HBV DNA were (6.41±0.60) log 10 copies/ml, and HBeAg were (569.8±418.1) S/CO. They were categorized into different groups according to the changes of HBeAg at week 24. The groups have no differences in HBeAg, HBV DNA, ALT and sex ratio at baseline. The diagnosis standard is consistent with Chinese Guideline of CHB. 2 The presence of HBsAg in serum existed for more than 6 months, HBeAg was positive, HBV DNA >10 4 copies/ ml, the baseline of ALT was between 2×upper limit of normal (ULN) and 10×ULN, TBil<2×ULN, they have not accepted any antiviral therapy or any immunity adjustment therapy one-year before therapy. The contraindication of the antiviral therapy had been excluded.
Methods
Patients were treated with Peg-IFN-α 2a at a dose of 135 μg/week (weight ≤ 65 kg) or 180 μg/week (weight > 65 kg) for 24 weeks, they were categorized into 3 groups according to the change of HBeAg in week 24: a HBeAg decline > 2 log 10 group (group A), a HBeAg decline between 1 1og 10 -2 log 10 (group B), a HBeAg decline < 1 log 10 group (group C), group C was randomly distributed into C1 and C2. The patients in group A, group B, and group C1 continued the original therapy and the patients in group C2 were given lamivudine plus Peg-IFN-α 2a for 24 weeks. Serum ALT, HBV DNA, HBsAg, HBeAg and antiHBe levels were measured at baseline and during therapy (week 12, 24, 36 and 48) . ALT was detected by completely automatic biochemistry analyzer. Serum HBsAg, HBeAg and anti-HBe levels were measured by Abbott Achitect, results were calculated based on the ratio of the sample (S) to the cut-off (CO) values for each sample and control. Samples Notes: Ninety-six HBeAg positive CHB patients who have accepted Peg-IFN therapy were enrolled, they were categorized into 3 groups according to the change of HBeAg at week 24, a HBeAg decline > 2 log 10 group (group A), a HBeAg decline between 1 1og 10 -2 log 10 (group B), a HBeAg decline < 1 log group (group C), group C was randomly distributed into C1 and C2. The patients in group A, group B, and group C1 continued the original therapy and the patients in group C2 were given lamivudine plus Peg-IFN-α 2a for 24 weeks.
with S/CO <1.0 were considered to be negative for HBeAg. Samples with S/CO <1.0 were considered to be positive for anti-HBe. HBeAg seroconversion was defined as the loss of HBeAg accompanied by detection of anti-HBe. HBV DNA and HBV cccDNA were detected in liver sample by Roche Light-cycler FQ-PCR. At week 48, the treatment efficacy and hepatitis B virus covalently closed circular DNA (HBV cccDNA) in liver biopsies were analyzed ( Figure 1 ).
Statistical analysis
Data analysis was described using means ± SD or medians (with interquartile ranges). Comparisons between group A, group B and group C were performed using the Nemenyi method. Comparisons between group C1 and group C2 were made using the Mann-Whitney test. Comparisons of HBV DNA loss and HBeAg seroconversion were performed using the Chi-square test. All analyses were performed using SPSS software (Inc., Chicago, IL, USA) for Windows (release 17.0). P < 0.05 was considered statistically significant.
RESULTS
Mean reduction of serum HBV DNA at week 48
Group A: 5.8 log 10 copies/ml, group B: 3.8 log 10 copies/ml, group C1: 2.8 log 10 copies/ml, group C2: 5.7 log 10 copies/ml. The mean reduction of serum HBV DNA in group A was greater than that in groups B and C1 (Nemenyi display: χ 2 AB =9.06, P < 0.05; χ 2 AC1 = 23.45, P < 0.05), and that in group C1 was greater than that in group C2 (Mann-Whitney U display: U=44.0, W=320.0, P C1C2 <0.01), the difference between groups B and C1 had no statistical significance (Nemenyi display: χ 2 BC1 =3.28, P = 0.19). Mean reduction of HBeAg: group A: 2.7 log 10 S/CO, group B: 1.9 log 10 S/CO, group C1: 0.9 log 10 S/CO, group C2: 1.6 log 10 S/CO. The differences among groups A, B and C1 (Nemenyi display: χ 2 AB =10.58, P < 0.05; χ 2 AC1 =43.32, P < 0.05; χ 2 BC1 =10.82, P < 0.05) and between groups C1 and C2 (Mann-Whitney U display: U=109.0, W=385.0, P C1C2 <0.01) were statistically significant.
Serum HBeAg kinetics according to the treatment response
Group A had a significant decrease in the first 24 weeks, groups C1 and C2 had a slower decrease in the first 24 weeks in comparison with groups A and B. Group C2 had a more markedly decrease than group C1 after adding lamivudine in the last 24 weeks (Figure 2 ). Serum HBV DNA kinetics according to the treatment response: group A had a significant decrease in the first 24 weeks, group B had a slower decrease in the first 24 weeks than group A and reached the lower limit of detection of serum HBV DNA in week 36. Groups C1 and C2 had a small decrease in the first 24 weeks, Group C2 had a more remarkable decrease than group C1 after adding lamivudine in the last 24 Notes: Serum HBV DNA kinetics according to the treatment response: group A had a significant decrease in the first 24 weeks, group B had a slower decrease in the first 24 weeks than group A and reached the lower limit of detection of serum HBV DNA in week 36. Groups C1 and C2 had a small decrease in the first 24 weeks, group C2 had a more remarkable decrease than group C1 after adding lamivudine in the last 24 weeks. weeks (Figure 3 ).
Therapy effects in each group
At week 48, HBV DNA undetectable rates in group A, group B, group C1 and group C2 were 87.5% (21/24), 34.5% (10/29), 17.4% (4/23) and 85.0% (17/20) respectively. HBV DNA undetectable rate in group A was greater than in groups B and C1 (χ 2 AB =15.203, P < 0.01; χ 2 AC1 =23.186, P < 0.01), that in group C1 was greater than in group C2 (χ 2 =19.570, P < 0.01), the difference between groups B and C1 had no statistical significance (χ 2 BC1 =1.904, P = 0.168). HBeAg seroconversion rates were 75.0% (18/24), 24.1% (7/29), 13.0% (3/23) and 25.0% (5/20) respectively, that in group A was greater than in groups B and C1 (χ 2 AB =13.632, P < 0.01; χ 2 AC1 =18.240, P < 0.01). The difference between groups B and C1 and between groups C1 and C2 had no statistical significance (χ 2 BC1 = 1.016, P = 0.313; χ 2 C1C2 = 1.010, P = 0.315). ALT normalization rate in group A, group B, group C1 and group C2 were 70.8% (17/24), 24.1% (7/29), 13.0% (3/23) and 25.0% (5/20) respectively, and that in group A was greater than in groups B and C1 (χ 2 AC1 = 10.326, P < 0.01; χ 2 BC1 = 11.460, P = 0.168). The difference between groups B and C1 and between groups C1 and C2 had no statistical significance (χ 2 AB = 0.006, P = 0.939; χ 2 C1C2 = 1.691, P = 0.193) ( Table 1  and Table 2 ).
Therapy effects on cccDNA
At week 48, group A had lower HBV cccDNA in liver tissue than group B and group C1 (Nemenyi display: χ 2 AB = 6.78, P < 0.05; χ 2 AC1 = 11.63, P < 0.05). The difference of HBV cccDNA between groups B and C1 or between groups C1 and C2 had no statistical significance (Nemenyi display: χ 2 BC1 = 0.60, P = 0.74; Mann-Whitney U display: U=109.0, W=385.0, P C1C2 < 0.01) ( Table 3) .
Safety
The frequency and severity of adverse events were Table 4 . Untoward effect during the therapy usually transient. In 1-4 weeks, the most frequent serous adverse events occurred in eighty-four patients were fever, lacking in strength and flu like symptoms, the adverse events reduced during the prolonged treatment time. At week 48, 50% of patients had neutropenia, 11.5% of patients had thrombocytopenia. Serious myelosuppression, liver function damage, thyrotoxicosis and psychosis were not observed during the treatment. The groups did not differ in the incidence of fever, lacking in strength, flu like symptoms, neutropenia or thrombocytopenia (Table 4) .
DISCUSSION
Reduction of HBV DNA is an excellent indicator of antiviral efficacy. However, a decrease in HBV DNA alone may be transient, particularly once antiviral agents are discontinued. 3,4 Seroconversion of HBeAg is another surrogate endpoint that is considered to be a marker for durable therapeutic response and had decreased liver-related morbidity and mortality.
5,6
The evaluation standards of antiviral therapy are the decrease of HBV DNA and HBeAg, HBV DNA undetectable rate, HBeAg seroconversion rate, ALT normalization rate and HBV cccDNA. To assess on-treatment serum HBeAg kinetics to predict outcomes of interferon antiviral therapy has been found useful for the realization of individual antiviral treatment. Previous studies have identified that HBeAg at baseline can be a predictor for the treatment effect of Peg-IFN-α 2a on HBeAg-positive CHB patients 8 . In this study, CHB patients who showed an HBeAg decline of > 2 log 10 had a higher HBeAg and HBV DNA decrease, a higher HBV DNA undetectable rate and HBeAg seroconversion rate, and a lower HBV cccDNA than those who showed an HBeAg decline of < 2 log 10 at week 24. CHB patients who showed an HBeAg decline of >2 log 10 at week 24 of Peg-IFN-α 2a treatment had better treatment outcomes at week 48 than those who showed an HBeAg decline of < 2 log 10 at week 24.
To investigate individualized plan of antiviral therapy, the patients in group C2 were given lamivudine plus Peg-IFN-α 2a for 24 weeks, the results showed that the combination of Peg-IFN-α 2a and lamivudine can improve the clinical responses, group C2 had a higher HBeAg and HBV DNA decrease and a higher HBV DNA undetectable rate than group C1. Previous studies have proved several factors that were associated with a higher likelihood of HBeAg seroconversion, including low serum HBV DNA levels after antiviral therapy and prolonged antiviral therapy. So it is necessary to prolong the combined antiviral therapy and investigate the value of it. 9
In conclusion, CHB patients who showed an HBeAg decline of > 2 log 10 at week 24 with Peg-IFN-α 2a treatment had better treatment outcome at week 48 than those who showed HBeAg decline < 2 log 10 at week 24. Augmenting the Peg-IFN-α 2a treatment with lamivudine could improve the clinical response. A change of quantifiable HBeAg at week 24 of Peg-IFN-α 2a treatment may be a useful predictor of therapeutic efficacy of 48-week antiviral regimen.
